Overview

Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

Status:
Not yet recruiting

Trial end date:
2024-03-15

Target enrollment:

Participant gender:

Summary

This is a single arm phase II, multicenter study evaluating Pembrolizumab in recurrent platinum resistant CPS score >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients.

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab